Michael Conick Hanley
Operationeel Directeur bij ALTO NEUROSCIENCE, INC.
Vermogen: 50 608 $ op 31-05-2024
Actieve functies van Michael Conick Hanley
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ALTO NEUROSCIENCE, INC. | Operationeel Directeur | 20-05-2024 | - |
Loopbaan van Michael Conick Hanley
Eerdere bekende functies van Michael Conick Hanley
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| SPYRE THERAPEUTICS, INC. | Corporate Officer/Principal | 04-11-2019 | 14-04-2023 |
Esteve Pharmaceuticals S.A.
 Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Corporate Officer/Principal | 01-04-2018 | 01-09-2019 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Verkoop & Marketing | 01-07-2015 | 01-06-2017 |
Opleiding van Michael Conick Hanley
| Kellogg School of Management | Masters Business Admin |
| Notre Dame University | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 4 |
| Libanon | 2 |
| Spanje | 2 |
Operationeel
| Corporate Officer/Principal | 2 |
| Masters Business Admin | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| ALTO NEUROSCIENCE, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Esteve Pharmaceuticals S.A.
Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Health Technology |
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
